Someone else's clock has started running against them: the company is being paid to solve a problem that is already cost
The model's full reasoning — Q2 2023 call → NOWe need to determine if management describes that counterparties are already losing something real and ongoing, and that this is visible in their behavior. The question asks specifically about "ITS COUNTERPARTIES" - customers, partners, etc. We need both halves: (1) a running meter on the other side, (2) the other side already acting like the meter is running. Also, management should convey that this dynamic is generating business meaningful relative to company size and still ahead. Looking at the transcript: Brian and Johnny discuss various aspects. They mention growth, system placements, reagent pull-through, new products, etc. They talk about biopharma and CRO partners leveraging platforms. They discuss the PhenoCycler-Fusion and HT. They mention "growing momentum within our biopharma and CRO partners as they leverage the PhenoImager HT platform to address their growing biomarker needs." That's a benefit, not necessarily a running cost. They talk about the CLIA Lab and CRO network. They mention that "biopharma partners are looking to outsource projects" and they have options. They talk about targeted investments to drive growth. They mention that "our customers" are using the platforms. However, the key is whether management describes an accumulating loss on the counterparty side that is already visible in behavior. They mention that customers are adopting, but is there a sense that waiting is expensive? They mention "time from sample to answer" improvements, but not that customers are losing money or opportunities by not having it. They talk about "driving increased reagent pull-through" and "system utilization." That's about company's revenue. They mention "the transformative power of Akoya solutions has been validated" with publications. That's not a running meter. They mention "biopharma and CRO partners as they leverage the PhenoImager HT platform to address their growing biomarker needs." That's a need, but not an accumulating loss. They also mention "clinical market development" and "qualified CRO service provider network." That's about expanding ecosystem. They talk about "operational efficiencies" and "cash flow positivity." They mention competitive dynamics but not that customers are rushing. Is there any mention of customers pressing for earlier delivery or something? I don't see that. They talk about field upgrades, but that's internal.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
SYM · Q3 2022 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...YES The transcript shows management describing customers' ongoing pain from labor shortages and broken supply chains that prevent them from handling demand, with customers actively clamoring for faster deployments and wanting the system as quickly as possible.
CRL · Q2 2022 → YESThe question is whether management describes that their counterparties are already losing something real and ongoing — money, output, access, standing, time, or an opportunity — for as long as they do...
GTES · Q4 2021 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...